医学
疾病
神经炎症
阿尔茨海默病
临床试验
单克隆抗体
淀粉样蛋白(真菌学)
随机对照试验
肿瘤科
内科学
免疫学
抗体
病理
作者
Madia Lozupone,Vittorio Dibello,Rodolfo Sardone,Fabio Castellana,Roberta Zupo,Luisa Lampignano,Ilaria Bortone,Roberta Stallone,Mario Altamura,Antonello Bellomo,Antonio Daniele,Vincenzo Solfrizzi,Francesco Panza
标识
DOI:10.1080/17460441.2024.2348142
摘要
Introduction In the last decade, the efforts conducted for discovering Alzheimer's Disease (AD) treatments targeting the best-known pathogenic factors [amyloid–β (Aβ), tau protein, and neuroinflammation] were mostly unsuccessful. Given that a systemic failure of Aβ clearance was supposed to primarily contribute to AD development and progression, disease-modifying therapies with anti-Aβ monoclonal antibodies (e.g. solanezumab, bapineuzumab, gantenerumab, aducanumab, lecanemab and donanemab) are ongoing in randomized clinical trials (RCTs) with contrasting results.
科研通智能强力驱动
Strongly Powered by AbleSci AI